Ciprofloxacin
Small molecule targets CYP1A2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 17 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | OTIPRIO | — | 2018-03-02 | fda.gov ↗ |
| Label expansions (9) | US (FDA) | CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER | — | 1996-10-10 – 2015-02-02 | fda.gov ↗ |
| Label expansions (5) | US (FDA) | CIPRO | — | 1994-07-21 – 1997-06-03 | fda.gov ↗ |
| Label expansion | US (FDA) | CILOXAN | — | 1994-10-27 | fda.gov ↗ |
| Approved | US (FDA) | CIPRO | — | 1987-10-22 | fda.gov ↗ |
Trials 161 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT00881907 | Mar 2010 → Mar 2014 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 0 | NCT00881491 | Apr 2009 → Jan 2015 | dental pulp necrosis | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 129 trials | ||||||
| Phase 1 | NCT06925490 | Jun 2025 → Sep 2026 expected | pulpitis | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06478940 | Aug 2024 → Aug 2025 | dental pulp disorder | Cairo University | Unknown | No outcome recorded |
| Phase 1 | NCT05724628 | Oct → Nov 2023 | appendicitis | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05843708 | Apr → Jul 2023 | — | Servier Bio-Innovation LLC | Completed | No outcome recorded |
| Phase 1 | NCT04090684 | Dec 2019 → Sep 2021 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04523987 | Feb 2019 → Feb 2027 expected | pancreatic ductal adenocarcinoma | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01976065 | Sep 2014 → Sep 2018 | dental pulp necrosis | Kenneth Hargreaves | Completed | No outcome recorded |
| Phase 1 | NCT02118909 | May → Jun 2014 | — | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 1 | NCT02015507 | Jan → Feb 2014 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01952444 | Oct 2013 → Apr 2014 | inhalational anthrax | Elusys Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00992329 | Jan → Nov 2013 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT01768663 | Jan → Sep 2013 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT01538667 | Apr → Jul 2012 | respiratory system disorder | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01402947 | Jul → Aug 2011 | — | Shire | Completed | No outcome recorded |
| Phase 1 | NCT01386593 | May 2011 → Jan 2012 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01168895 | Jul → Sep 2010 | chronic obstructive pulmonary disease, infectious disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01072942 | Jan → Jun 2010 | chronic obstructive pulmonary disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01059890 | Sep 2009 → Jun 2013 | bacterial infectious disease, brain injury | Poitiers University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00961038 | Aug 2009 → Mar 2010 | chronic obstructive pulmonary disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00964561 | Aug 2009 → Feb 2010 | anthrax infection | PharmAthene, Inc. | Suspended | No outcome recorded |
| Phase 1 | NCT00832286 | Jul 2009 → Sep 2010 | colonic disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00910351 | Jul 2009 → Oct 2010 | Pseudomonas infection | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT01052298 | Apr → Sep 2009 | chronic obstructive pulmonary disease | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT00785980 | Sep → Oct 2008 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00649155 | Nov 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649662 | Oct 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00138411 | Oct 2005 → Mar 2006 | anthrax infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01372345 | Feb 2005 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01372358 | Jan 2005 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06126731 | Nov 2023 → Jun 2026 overdue | castration-resistant prostate carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02773732 | Dec 2016 → Sep 2021 | acute myeloid leukemia | University of Florida | Terminated | No outcome recorded |
| Phase 1/2 | NCT01108601 | Apr 2008 → Apr 2011 | hearing loss disorder | McGill University Health Centre/Research Institute of the McGill University Health Centre | Unknown | No outcome recorded |
| Phase 228 trials | ||||||
| Phase 2 | NCT07028424 | Jul 2025 → Jul 2029 expected | pancreatic ductal adenocarcinoma | GERCOR - Multidisciplinary Oncology Cooperative Group | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06728072 | Mar 2025 → Jul 2035 expected | colorectal cancer | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 2 | NCT06798402 | Feb → Nov 2025 overdue | cutaneous leishmaniasis | Al-Mustafa University College | Recruiting | No outcome recorded |
| Phase 2 | NCT07264842 | Jun 2024 → Apr 2026 overdue | dental pulp necrosis | Dow University of Health Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06342830 | Jun 2024 → Sep 2025 | periapical periodontitis | Ain Shams University | Completed | No outcome recorded |
| Phase 2 | NCT05462496 | Mar 2023 → Aug 2027 expected | malignant pancreatic neoplasm | Icahn School of Medicine at Mount Sinai | Recruiting | No outcome recorded |
| Phase 2 | NCT05205993 | Jan 2021 → Jan 2024 | chronic endometritis | Genesis Athens Clinic | Unknown | No outcome recorded |
| Phase 2 | NCT04165850 | Nov 2019 → Jan 2021 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04067011 | Aug 2019 → Mar 2020 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 2 | NCT05287425 | Aug 2019 → Aug 2023 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2 | NCT02682485 | Mar 2017 | intestinal perforation, rectal cancer | University of Chicago | Withdrawn | No outcome recorded |
| Phase 2 | NCT04447625 | Mar 2017 → Feb 2019 | chronic endometritis | Genesis Athens Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02252978 | Jul 2016 | prostate cancer | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT02719158 | Feb → Jun 2016 | otitis media | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02620007 | Dec 2015 → Aug 2021 | Crohn disease | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 2 | NCT01783106 | Feb 2014 → Apr 2019 | Crohn disease | Royal Liverpool University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01753115 | Dec 2012 → Aug 2013 | anthrax infection | Emergent BioSolutions | Completed | No outcome recorded |
| Phase 2 | NCT01279252 | Jul 2011 → Jan 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | King's College Hospital NHS Trust | Completed | No outcome recorded |
| Phase 2 | NCT01359098 | Jul → Oct 2011 | acute otitis externa | Otic Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01243437 | Dec 2010 → Jun 2013 | plague | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00889967 | Feb 2010 → Apr 2011 | bronchiectasis | Aradigm Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00930982 | Jun 2009 → Sep 2010 | bronchiectasis | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00645788 | May 2008 → Jan 2011 | cystic fibrosis | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00257699 | May 2006 → Jul 2008 | Crohn's colitis | Mount Sinai Hospital, Canada | Terminated | No outcome recorded |
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00438269 | Feb 2003 → Mar 2005 | nosocomial infection, pneumonia | Canadian Critical Care Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT04552431 | Sep 1997 → Aug 2003 | chronic prostatitis | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00000641 | ? → Dec 1994 | HIV infectious disease, Mycobacterium avium complex disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07202052 | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05678621 | Nov 2022 → Apr 2027 expected | dysgammaglobulinemia, hematopoietic and lymphoid cell neoplasm | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04879030 | Jan → Aug 2020 | chronic obstructive pulmonary disease | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT04319575 | Dec 2018 → Apr 2020 | suppurative periapical periodontitis | Dr. D. Y. Patil Dental College & Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT07113587 | Apr 2014 → Jul 2017 | infectious peritonitis | Karl Landsteiner Insitute for Nephrology and Haemato-Oncology | Completed | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT07686055 | Jul 2026 → Feb 2027 expected | urinary tract infection | Megan Bradley | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05079802 | Dec 2021 → Dec 2023 | tooth resorption | Ain Shams University | Unknown | No outcome recorded |
| Phase 3 | NCT04636957 | Nov 2020 → Dec 2021 | acute otitis externa | Lee's Pharmaceutical Limited | Unknown | No outcome recorded |
| Phase 3 | NCT04110340 | Feb 2020 → Apr 2024 | bubonic plague, pneumonic plague | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT03303677 | Apr → Nov 2018 | chronic rhinosinusitis | University of Florida | Withdrawn | No outcome recorded |
| Phase 3 | NCT04547764 | Jun 2017 → Dec 2018 | dental pulp disorder | King Abdulaziz University | Completed | No outcome recorded |
| Phase 3 | NCT02389036 | May 2017 → Apr 2023 | critical illness polyneuropathy, infectious disease with sepsis | The George Institute | Completed | No outcome recorded |
| Phase 3 | NCT02795949 | Oct 2016 → Jan 2020 | bacterial infectious disease | Andalusian Public Foundation for Health Research in Seville | Completed | No outcome recorded |
| Phase 3 | NCT02801370 | Jun → Nov 2016 | acute otitis externa | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02600559 | Oct 2015 → Jul 2016 | otitis media | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02216071 | Jul 2014 → Aug 2015 | acute otitis externa | Exela Pharma Sciences, LLC. | Completed | No outcome recorded |
| Phase 3 | NCT02104245 | May 2014 → Aug 2016 | bronchiectasis | Aradigm Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02106832 | Apr 2014 → Sep 2016 | bronchiectasis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01515007 | Mar 2014 → Aug 2016 | bronchiectasis | Aradigm Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01949142 | Nov 2013 → May 2014 | otitis media with effusion | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01949155 | Nov 2013 → May 2014 | otitis media with effusion | Otonomy, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01764841 | May 2013 → Mar 2016 | bronchiectasis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01561794 | May 2012 → Mar 2015 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00980876 | Apr 2012 → Jan 2015 | acute otitis externa | Farmoquimica S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01733966 | May 2010 → Mar 2012 | diverticulitis of colon | Quanta Medical | Terminated | No outcome recorded |
| Phase 3 | NCT00741052 | Jul 2007 → Oct 2008 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00137787 | Apr 2005 → Dec 2009 | neutropenia | Center for Supporting Hematology-Oncology Trials | Completed | No outcome recorded |
| Phase 3 | NCT00670215 | Apr → Oct 2004 | bacterial infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00668122 | Mar 2004 → Jan 2006 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00107081 | Jan 2004 → Dec 2007 | cancer, neutropenia | Swiss Pediatric Oncology Group | Terminated | No outcome recorded |
| Phase 3 | NCT00668044 | Nov 2002 → Nov 2003 | bacterial infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00142272 | May 2001 → Jul 2002 | cholera | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT00761462 | Oct 1999 → Jan 2008 | infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00003824 | Apr 1999 → Jul 2001 | bladder transitional cell carcinoma | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 3 | NCT00002850 | Mar 1997 → Apr 2011 | bacterial infectious disease, plasma cell myeloma | Gary Morrow | Completed | No outcome recorded |
| Phase 435 trials | ||||||
| Phase 4 | NCT07704359 | Aug 2026 → Feb 2029 expected | anal fistula | University of Illinois at Chicago | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06709196 | Jan 2025 → Jan 2027 expected | urinary bladder cancer | Rigshospitalet, Denmark | Recruiting | No outcome recorded |
| Phase 4 | NCT05398679 | Aug 2022 → Dec 2026 expected | infective endocarditis | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 4 | NCT05600023 | Aug → Oct 2022 | pulpitis | Altamash Institute of Dental Medicine | Completed | No outcome recorded |
| Phase 4 | NCT05199324 | Jun 2022 → May 2026 overdue | gram-negative bacterial infections | Tan Tock Seng Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04948463 | Nov 2021 → Dec 2025 | neutropenia | Murdoch Childrens Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03891979 | Jun 2019 → Jun 2020 | malignant pancreatic neoplasm | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 4 | NCT03347461 | Oct 2018 → Jun 2019 | discharging ear, otitis media with effusion | Boston Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03692715 | Sep 2018 → Dec 2024 | nephrolithiasis, ureterolithiasis | Clinical Urology and Epidemiology Working Group | Completed | No outcome recorded |
| Phase 4 | NCT04456712 | Jun → Nov 2018 | — | Beni-Suef University | Completed | No outcome recorded |
| Phase 4 | NCT03228108 | Apr 2018 → Sep 2021 | infectious disease, prostate cancer | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03012360 | Feb 2018 → Jul 2024 | — | University Hospital, Lille | Terminated | No outcome recorded |
| Phase 4 | NCT03366207 | Dec 2017 → Jul 2018 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 4 | NCT03051698 | Nov 2016 → Oct 2019 | asthma | T. van der Poll | Terminated | No outcome recorded |
| Phase 4 | NCT02357407 | Jun 2015 → Dec 2016 | infectious disease | Rennes University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02505581 | May 2015 → Apr 2017 | — | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02598362 | Apr 2015 → May 2017 | pyelonephritis | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02375295 | Mar 2015 → Dec 2023 | urolithiasis | University of British Columbia | Unknown | No outcome recorded |
| Phase 4 | NCT03533231 | Jan 2015 → Oct 2017 | acute apical periodontitis, dental abscess, dental pulp necrosis | Tariq Yehia | Completed | No outcome recorded |
| Phase 4 | NCT02173262 | Aug 2014 → Sep 2017 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01723150 | Nov 2013 → Jan 2018 | liver abscess (disease) | National University Hospital, Singapore | Completed | No outcome recorded |
| Phase 4 | NCT01659866 | Aug 2012 → Aug 2015 | infectious disease | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT01542801 | Aug 2011 → Jul 2015 | drug allergy | Korea University | Completed | No outcome recorded |
| Phase 4 | NCT01772615 | May 2011 → Aug 2013 | ulcerative colitis | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00809913 | Dec 2008 → May 2013 | urinary tract infection | Leiden University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00596453 | Jan 2008 → Jun 2011 | prostatitis | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 4 | NCT01265173 | Apr 2007 → Jun 2018 | cirrhosis of liver | Korea University | Completed | No outcome recorded |
| Phase 4 | NCT00126698 | Jan 2005 → Apr 2007 | bacteriuria, urinary tract infection | St. Antonius Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00481689 | May 2004 → Sep 2005 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00669994 | Jul → Oct 2003 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00676533 | Jun 2003 → Jan 2004 | urinary tract infection | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00392275 | Nov 2002 → May 2006 | cataract | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT01329588 | Mar 2001 → Apr 2002 | HIV infectious disease, chlamydia trachomatis infectious disease, gonorrhea | CHU de Quebec-Universite Laval | Completed | No outcome recorded |
| Phase 4 | NCT00367913 | Mar 1995 → Sep 2004 | lung disorder | British Thoracic Society | Completed | No outcome recorded |
| Phase 4 | NCT00760032 | — | cirrhosis of liver, infectious disease | Florencia Vargas-Vorackova | Withdrawn | No outcome recorded |
| Phase not applicable29 trials | ||||||
| — | NCT07239739 | Jun → Nov 2026 expected | periapical periodontitis | Faiz ur rahman | Not yet recruiting | No outcome recorded |
| — | NCT07552870 | Jan → Apr 2026 | cirrhosis of liver | Shahida Islam Medical Complex | Completed | No outcome recorded |
| — | NCT07188935 | Oct 2024 → Jun 2025 | type 2 diabetes mellitus | Al-Mustansiriyah University | Completed | No outcome recorded |
| — | NCT07123792 | Jun 2024 → May 2025 | periodontal disorder | HITEC-Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT06158451 | Mar → Aug 2024 | periapical periodontitis | Cairo University | Unknown | No outcome recorded |
| — | NCT05750966 | Jul 2023 → Apr 2026 | cholangitis | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT04678869 | Jun 2022 → Jan 2028 expected | acute lymphoblastic leukemia | University College, London | Active not recruiting | No outcome recorded |
| — | NCT05286931 | Mar 2022 → Dec 2025 overdue | gonorrhea | University of Washington | Recruiting | No outcome recorded |
| — | NCT05024188 | Jan → Jul 2022 | — | Assaf Harofeh MC | Unknown | No outcome recorded |
| — | NCT04593238 | Nov 2020 → Apr 2021 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04763070 | Oct 2020 → Apr 2021 | epilepsy | Mazandaran University of Medical Sciences | Completed | No outcome recorded |
| — | NCT04003181 | Sep 2017 → May 2021 | colon adenocarcinoma, diarrheal disease | University of Aarhus | Completed | No outcome recorded |
| — | NCT05581706 | Sep 2017 → Feb 2020 | — | Ege University | Completed | No outcome recorded |
| — | NCT02961751 | Oct 2016 → Jan 2019 | gonorrhea | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT02189668 | Jul 2014 → Jul 2015 | appendicitis | Peter Minneci | Terminated | No outcome recorded |
| — | NCT02127749 | Jun 2014 → Dec 2015 | — | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT01929460 | Jan → Nov 2014 | pancreas disorder | Kaiser Permanente | Completed | No outcome recorded |
| — | NCT02033408 | Jan 2014 → Dec 2018 | Crohn's colitis, ulcerative colitis | Shaare Zedek Medical Center | Completed | No outcome recorded |
| — | NCT02196740 | Jun 2013 → Dec 2014 | periapical periodontitis | Lin Jiacheng | Unknown | No outcome recorded |
| — | NCT02340182 | Mar → Sep 2013 | infectious disease with sepsis | W.J. Wiersinga, MD, PhD | Completed | No outcome recorded |
| — | NCT01785641 | Dec 2012 → Dec 2013 | peritonitis | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT01572558 | Feb → Oct 2012 | appendicitis | Karolinska University Hospital | Completed | No outcome recorded |
| — | NCT01344512 | Jun 2011 → Sep 2014 | — | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01137903 | Apr 2010 → Apr 2011 | osteomyelitis, ulcer of lower limbs | Universidad Complutense de Madrid | Unknown | No outcome recorded |
| — | NCT00355602 | Jul 2006 → Dec 2008 | ulcerative colitis | University of Dundee | Completed | No outcome recorded |
| — | NCT00190151 | Sep 2004 → Jul 2005 | — | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| — | NCT00153634 | Mar 2004 → Nov 2007 | chronic bronchitis, cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| — | NCT00062231 | Apr 2002 → Oct 2006 | cancer of unknown primary site, infectious disease, leukemia, myelodysplastic syndrome +5 | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| — | NCT00713999 | Aug 2001 → Apr 2002 | sexually transmitted disease, urinary schistosomiasis | University of Aarhus | Completed | No outcome recorded |
Also used as a comparator or background therapy in 157 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT05100654 Comparator | Apr 2022 → Dec 2027 expected | erectile dysfunction, prosthesis-related infectious disease | University of Chicago | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05442736 Comparator | Apr 2022 | infectious disease | British University In Egypt | Completed | No outcome recorded |
| Phase 0 | NCT06149676 Background | Feb 2022 → Dec 2024 | urinary tract infection | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | No outcome recorded |
| Phase 0 | NCT03326050 Comparator | Feb → Sep 2018 | rhinoscleroma | Assiut University | Unknown | No outcome recorded |
| Phase 0 | NCT02326103 Comparator | Apr 2015 → Jan 2017 | alcoholic hepatitis, alcoholic liver cirrhosis | University of Helsinki | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 0 | NCT01731236 Comparator | Feb 2011 → Dec 2027 expected | — | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 119 trials | ||||||
| Phase 1 | NCT06810583 Background | May 2025 → Sep 2030 expected | acute myeloid leukemia, childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05959616 Background | Jan 2025 → Apr 2026 overdue | shigellosis | University of Oxford | Recruiting | No outcome recorded |
| Phase 1 | NCT05844735 Comparator | May → Oct 2023 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT05431673 Comparator | Aug 2022 → Jun 2023 | rhinoscleroma | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT05436678 Comparator | Jul → Aug 2022 | — | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05232461 Comparator | Apr 2022 | — | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04147260 Comparator | Nov 2019 → Sep 2020 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT03519516 Comparator | Jan → May 2018 | bacterial conjunctivitis | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 1 | NCT03840811 Background | Apr 2017 → Nov 2019 | gonorrhea | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02947763 Comparator | Nov 2016 → Jan 2018 | periapical periodontitis | Cairo University | Completed | No outcome recorded |
| Phase 1 | NCT03177720 Comparator | May 2016 → Jul 2021 | pneumonia | Medical University of Vienna | Completed | No outcome recorded |
| Phase 1 | NCT02532192 Background | Dec 2015 → Dec 2019 | lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT02114671 Comparator | Apr → Oct 2014 | — | Boehringer Ingelheim | Withdrawn | No outcome recorded |
| Phase 1 | NCT04870138 Background | Mar 2013 → Apr 2015 | gonorrhea | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01124799 Comparator | Jul 2010 → Apr 2011 | hepatitis C virus infection | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 1 | NCT00688272 Comparator | Jun → Sep 2008 | thrombocytopenic purpura | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00654108 Background | Jun 2008 → May 2010 | gastroenteritis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00650351 Comparator | Oct 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00004216 Background | Aug 1999 → Jan 2008 | cancer of unknown primary site | Vion Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02036528 Background | Jan → Dec 2014 | ulcer of lower limbs | Royer Biomedical, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT00872209 Comparator | May → Oct 2009 | otitis externa | Otic Pharma | Completed | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT07150065 Comparator | Feb → Aug 2025 | typhoid fever | Avicenna Medical College Lahore | Completed | No outcome recorded |
| Phase 2 | NCT04791579 Comparator | Feb 2025 → Mar 2027 expected | urinary tract infection | University of Alberta | Recruiting | No outcome recorded |
| Phase 2 | NCT06368804 Background | Sep 2024 → Mar 2025 overdue | bronchiectasis | Centre Hospitalier Intercommunal Creteil | Recruiting | No outcome recorded |
| Phase 2 | NCT06185543 Comparator | Nov 2023 → Sep 2025 | Alzheimer disease | NeuroSense Therapeutics Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT05357950 Comparator | May 2022 → Nov 2023 | amyotrophic lateral sclerosis | NeuroSense Therapeutics Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05294588 Background | Apr 2022 → Feb 2026 | gonorrhea | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT05162625 Comparator | Dec 2021 → Dec 2022 | acute endophthalmitis | University of Campinas, Brazil | Unknown | No outcome recorded |
| Phase 2 | NCT04238091 Comparator | Dec 2019 → Mar 2022 | alopecia areata, alopecia totalis, alopecia universalis | Lindsey Bordone | Withdrawn | No outcome recorded |
| Phase 2 | NCT04150250 Background | Nov 2019 → Jul 2020 | cholera | PATH | Completed | No outcome recorded |
| Phase 2 | NCT03476317 Background | Jul 2018 → Dec 2020 | Crohn disease | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT03850379 Comparator | Mar 2018 → Aug 2024 | disease related to hematopoietic stem cell transplant | Henry Ford Health System | Completed | No outcome recorded |
| Phase 2 | NCT03327844 Comparator | Mar 2017 → Jul 2021 | — | National University Health System, Singapore | Completed | No outcome recorded |
| Phase 2 | NCT02765256 Background | Aug 2016 → Dec 2018 | Crohn disease | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT02734732 Comparator | Apr 2015 → Apr 2020 | prostatitis | Umeå University | Unknown | No outcome recorded |
| Phase 2 | NCT02168816 Comparator | Mar 2014 → Feb 2017 | osteomyelitis | Loyola University | Terminated | No outcome recorded |
| Phase 2 | NCT01908803 Comparator | Dec 2013 → Aug 2014 | otitis media | Alcon Research | Terminated | No outcome recorded |
| Phase 2 | NCT01756924 Comparator | Dec 2012 → Jul 2014 | periprosthetic joint infection | Arrevus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT01928433 Comparator | Dec 2012 → Jun 2014 | acute pyelonephritis | MerLion Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 2 | NCT01505634 Background | May 2012 → Jul 2015 | pyelonephritis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01157819 Comparator | Jul → Nov 2010 | acute otitis externa | Otic Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00722735 Comparator | Oct 2008 → Apr 2009 | urinary tract infection | MerLion Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00609973 Comparator | May 2008 → Oct 2011 | Crohn disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT00303589 Comparator | Dec 2005 → Oct 2007 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT00097773 Comparator | Sep 2004 → Jun 2009 | chronic obstructive pulmonary disease, cystic fibrosis | Seattle Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00651586 Comparator | Oct 2003 → Apr 2005 | corneal ulcer | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT00139230 Background | Jan 1997 → Dec 2006 | head and neck carcinoma, squamous cell carcinoma | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07202091 Background | May 2025 → Mar 2027 expected | leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Monash University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06821763 Comparator | May → Oct 2025 overdue | periodontitis, pulpitis | Komal Ashraf Khan | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06006663 Comparator | Aug → Oct 2023 | — | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04204954 Background | May → Nov 2019 | cataract, demodicidosis, mite infestation | Hospital de La Luz | Completed | No outcome recorded |
| Phase 2/3 | NCT04030741 Comparator | Sep 2018 → Dec 2019 | appendicitis | King Edward Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT03622450 Comparator | Jan 2016 → Jan 2018 | — | Nourhan Hassan Osama Thuraya Mohamed | Completed | No outcome recorded |
| Phase 334 trials | ||||||
| Phase 3 | NCT07483736 Comparator | Mar 2026 → Mar 2028 expected | — | Versailles Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06055257 Background | Jan 2025 → Dec 2027 expected | osteoradionecrosis of the mandible | Sunnybrook Health Sciences Centre | Recruiting | No outcome recorded |
| Phase 3 | NCT06443502 Background | Nov 2024 → Dec 2029 expected | pouchitis | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT03630081 Background | Jan 2024 → Jan 2026 | acute pyelonephritis | Wockhardt | Unknown | No outcome recorded |
| Phase 3 | NCT05224401 Comparator | May 2023 → Sep 2027 expected | bacterial urinary tract infection | Lund University | Recruiting | No outcome recorded |
| Phase 3 | NCT06234046 Comparator | May → Nov 2023 | infectious peritonitis | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05384197 Comparator | May 2022 → May 2023 | nephrolithiasis | Mansoura University | Unknown | No outcome recorded |
| Phase 3 | NCT05074147 Background | May 2022 → Nov 2024 | osteomyelitis | Tourcoing Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT07616635 Comparator | Mar 2022 → May 2024 | acute leukemia, disease related to hematopoietic stem cell transplant | Fundación para la Investigación Biosanitaria del Principado de Asturias | Completed | No outcome recorded |
| Phase 3 | NCT04698057 Comparator | Mar 2022 → Jun 2025 | neutropenia | Poitiers University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT04549311 Comparator | Nov 2021 → Jan 2023 | anal fistula | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT03969758 Comparator | Jul 2019 → May 2020 | liver abscess (disease) | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT03358576 Comparator | Sep 2018 → Oct 2019 | intestinal infectious disease | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03357614 Comparator | Sep 2018 → Dec 2019 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03354598 Comparator | Aug 2018 → Jan 2020 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03196973 Comparator | Jul 2017 → Aug 2018 | acute otitis externa | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT02717871 Comparator | Mar 2016 → Oct 2020 | keratitis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 3 | NCT03862170 Comparator | Feb 2015 → Feb 2020 | prostate cancer | CR-CSSS Champlain-Charles-Le Moyne | Terminated | No outcome recorded |
| Phase 3 | NCT02579161 Comparator | Sep 2014 → Mar 2018 | urolithiasis | Northwell Health | Completed | No outcome recorded |
| Phase 3 | NCT02300220 Comparator | May 2014 → Jan 2019 | chronic obstructive pulmonary disease | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT02068846 Comparator | Apr 2014 → Jan 2016 | HIV infectious disease, benign lymphoepithelial lesion of salivary gland | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 3 | NCT02011841 Comparator | Jan 2014 → Dec 2015 | infectious peritonitis | Seoul National University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT01873690 Comparator | Nov 2013 → Dec 2015 | urolithiasis | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Terminated | No outcome recorded |
| Phase 3 | NCT01599806 Background | Oct 2012 → Aug 2014 | acute pyelonephritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01595438 Background | Oct 2012 → Aug 2014 | acute pyelonephritis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01404611 Comparator | Jun 2011 → May 2013 | otitis media | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT01208922 Comparator | Nov 2010 → Jan 2016 | acute diarrhea | Dr. Falk Pharma GmbH | Completed | No outcome recorded |
| Phase 3 | NCT00945802 Comparator | Jul 2009 → Jul 2010 | acute otitis externa | Shire | Terminated | No outcome recorded |
| Phase 3 | NCT00840294 Comparator | Jan 2009 → May 2011 | — | University of Chicago | Terminated | No outcome recorded |
| Phase 3 | NCT00736983 Comparator | Sep 2008 → Sep 2011 | perianal Crohn disease | Foundation for Liver Research | Completed | No outcome recorded |
| Phase 3 | NCT00598403 Comparator | Nov 2007 → Dec 2009 | urinary tract infection | Tedec-Meiji Farma, S.A. | Completed | No outcome recorded |
| Phase 3 | NCT00445497 Background | Jul 2007 → Jul 2010 | central nervous system neoplasm, lymphoma, neutropenia, small intestine cancer | Clatterbridge Centre for Oncology | Unknown | No outcome recorded |
| Phase 3 | NCT00791505 Comparator | Jul 2002 → Jun 2005 | chronic obstructive pulmonary disease, infectious disease with sepsis | University of Monastir | Completed | No outcome recorded |
| Phase 3 | NCT00590785 Background | Aug 1996 → Jun 1997 | breast cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 438 trials | ||||||
| Phase 4 | NCT07625267 Comparator | Jul 2026 → Jun 2028 expected | diverticulitis of colon | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07236944 Comparator | Dec 2025 → Mar 2029 expected | bacterial urinary tract infection | Uppsala University | Recruiting | No outcome recorded |
| Phase 4 | NCT07016165 Comparator | Jun → Nov 2025 overdue | acute lymphoblastic leukemia, acute myeloid leukemia, neutropenia | Gadjah Mada University | Recruiting | No outcome recorded |
| Phase 4 | NCT06093191 Comparator | Oct 2023 → Oct 2025 | Pseudomonas aeruginosa infectious disease, bronchiectasis | Shanghai Pulmonary Hospital, Shanghai, China | Completed | No outcome recorded |
| Phase 4 | NCT05846399 Comparator | Sep 2023 → Jul 2027 expected | cat-scratch disease | University of Missouri-Columbia | Recruiting | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT05274672 Comparator | Mar 2023 → Feb 2025 | benign prostatic hyperplasia, urinary tract infection | Baylor Research Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT05726318 Background | Feb 2023 → Aug 2024 | urinary tract infection | Megan Bradley | Completed | No outcome recorded |
| Phase 4 | NCT05719285 Comparator | Dec 2022 → Jun 2023 | overactive bladder | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 4 | NCT06818578 Background | Sep 2022 → Aug 2024 | dental pulp necrosis, pulpitis, teeth present at birth | Inonu University | Completed | No outcome recorded |
| Phase 4 | NCT05863832 Comparator | Aug 2021 → Dec 2023 | — | MinaPharm Pharmaceuticals | Unknown | No outcome recorded |
| Phase 4 | NCT04444440 Comparator | Jun 2021 → Jun 2026 overdue | overactive bladder, urinary tract infection | University of Alberta | Recruiting | No outcome recorded |
| Phase 4 | NCT03854929 Comparator | Dec 2019 → Feb 2021 | shigellosis | Oxford University Clinical Research Unit, Vietnam | Completed | No outcome recorded |
| Phase 4 | NCT03431675 Comparator | Mar → Jun 2019 | meningococcal meningitis | Epicentre | Withdrawn | No outcome recorded |
| Phase 4 | NCT03716804 Comparator | Jun → Dec 2018 | bacterial infectious disease, urinary tract infection | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Completed | No outcome recorded |
| Phase 4 | NCT03985514 Comparator | May 2018 → Jun 2021 | appendicitis | Göteborg University | Completed | No outcome recorded |
| Phase 4 | NCT03262142 Comparator | Jan 2018 → Mar 2023 | Pseudomonas aeruginosa infectious disease, asthma, bronchiectasis, respiratory tract infectious disorder | Chronic Obstructive Pulmonary Disease Trial Network, Denmark | Terminated | No outcome recorded |
| Phase 4 | NCT03220074 Background | Dec 2017 → Jun 2021 | mycobacterial infectious disease | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT03159754 Background | Jun 2017 → Mar 2020 | appendicitis | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT02724046 Comparator | Apr → May 2017 | meningococcal meningitis | Epicentre | Completed | No outcome recorded |
| Phase 4 | NCT03084601 Comparator | Mar 2017 → Jan 2018 | dental pulp necrosis | Mahmoud M Saadoon | Completed | No outcome recorded |
| Phase 4 | NCT02790138 Comparator | Oct 2016 → Jun 2020 | pouchitis | Takeda | Completed | No outcome recorded |
| Phase 4 | NCT02816112 Comparator | Sep 2016 → Mar 2020 | breast cancer | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT02423759 Comparator | Apr 2015 → Jan 2017 | benign prostatic hyperplasia | Mansoura University | Completed | No outcome recorded |
| Phase 4 | NCT02458781 Comparator | Jan 2015 → Jan 2018 | small intestinal bacterial overgrowth | San Antonio Military Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02261896 Comparator | Oct 2014 → Jul 2018 | pancreas disorder | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01888822 Comparator | Jun 2013 → Jun 2016 | cholelithiasis | University of Roma La Sapienza | Terminated | No outcome recorded |
| Phase 4 | NCT01789203 Comparator | Jan 2013 → Apr 2017 | polyomavirus infectious disease | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01803191 Comparator | Aug 2012 → Jan 2016 | urinary tract infection | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | Completed | No outcome recorded |
| Phase 4 | NCT01649635 Background | Jul 2012 → Jan 2014 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01749605 Comparator | Oct 2010 → Jan 2012 | cystitis | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT01111253 Comparator | May 2010 → Apr 2013 | diverticulitis of colon | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 4 | NCT00873626 Comparator | Jun 2009 → Aug 2011 | urinary tract infection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT00805558 Comparator | Feb → Dec 2009 | chronic periodontitis | Facultad Nacional de Salud Publica | Completed | No outcome recorded |
| Phase 4 | NCT02123628 Comparator | Jun 2007 → Jun 2010 | diabetes mellitus | Tourcoing Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00719056 Comparator | Aug 2004 → Dec 2005 | — | University of Athens | Completed | No outcome recorded |
| Phase 4 | NCT01400750 Comparator | Aug 2001 → Aug 2010 | cystic fibrosis | Universitaire Ziekenhuizen KU Leuven | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT06926322 Comparator | Oct 2025 → Aug 2027 expected | dental pulp necrosis, neuropathy, painful, root resorption | Ain Shams University | Enrolling by invitation | No outcome recorded |
| — | NCT06517264 Comparator | Nov 2024 → Apr 2026 overdue | diverticulitis of colon | Monica Mengual Ballester | Enrolling by invitation | No outcome recorded |
| — | NCT06080698 Comparator | Feb 2024 → May 2027 expected | gram-negative bacterial infections | Johns Hopkins University | Recruiting | No outcome recorded |
| — | NCT05677945 Background | Mar 2023 → Mar 2024 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT06174909 Comparator | Nov 2022 → Aug 2023 | — | Pakistan Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT03643198 Comparator | Mar 2022 | abscess, anal fistula | Germans Trias i Pujol Hospital | Unknown | No outcome recorded |
| — | NCT03939273 Comparator | Mar 2022 → Mar 2023 | autoinflammatory syndrome, coronary artery disorder | Radboud University Medical Center | Unknown | No outcome recorded |
| — | NCT05385887 Comparator | Dec 2021 → Dec 2024 | abscess, anal fistula | dr. IJM Han-Geurts | Unknown | No outcome recorded |
| — | NCT05804123 Background | Oct 2021 → Apr 2024 | respiratory tract infectious disorder | Anabio R&D | Completed | No outcome recorded |
| — | NCT04575493 Comparator | Oct 2020 | urinary tract infection | Islamia University of Bahawalpur | Completed | No outcome recorded |
| — | NCT04374188 Comparator | Sep 2019 → Sep 2021 | nephrolithiasis | Diaa Eldin Taha Ramadan Mohamed | Unknown | No outcome recorded |
| — | NCT05445362 Comparator | Feb 2019 → Aug 2020 | — | Reham Hassan | Completed | No outcome recorded |
| — | NCT03173053 Comparator | Feb 2018 → Oct 2021 | movement disorder, staphylococcus aureus infection | Radboud University Medical Center | Terminated | No outcome recorded |
| — | NCT03027635 Background | Jan 2017 → May 2019 | cirrhosis of liver | Nina Kimer | Terminated | No outcome recorded |
| — | NCT03763110 Comparator | Oct 2016 → Dec 2018 | dental pulp necrosis | Cairo University | Unknown | No outcome recorded |
| — | NCT03459599 Comparator | Oct 2016 → Mar 2017 | endometritis | Sarawak General Hospital | Completed | No outcome recorded |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
| — | NCT02944825 Comparator | Jan 2016 → Jan 2025 | urinary tract infection, urolithiasis | University of California, San Diego | Completed | No outcome recorded |
| — | NCT02358993 Comparator | Dec 2014 → Sep 2020 | prosthesis-related infectious disease, urinary tract infection | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT02223338 Comparator | Oct 2014 → May 2016 | primary bacterial infectious disease | Loma Linda University | Completed | No outcome recorded |
| — | NCT02304822 Comparator | Aug 2014 → Dec 2017 | nephrolithiasis | Guohua Zeng | Unknown | No outcome recorded |
| — | NCT02247960 Comparator | Jul 2014 → May 2016 | Clostridium difficile colitis, prostate cancer, urinary tract infection | University of Rochester | Terminated | No outcome recorded |
| — | NCT01761214 Comparator | Sep 2012 → Dec 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| — | NCT03507556 Background | Jun 2010 → Nov 2021 overdue | — | Jordan University of Science and Technology | Active not recruiting | No outcome recorded |
| — | NCT00194532 Comparator | Jun 2005 → Feb 2009 | cystitis | University of Washington | Completed | No outcome recorded |
Evidence & citations 34 cited values
Every value below carries the sentence it was read from. 322 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIPROFLOXACIN | “Patients will be provided with amoxycillin/clavulanic acid 1750-2000mg/250mg and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop, with...” NCT07202091 ↗315“oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral...” NCT00332163 ↗ “Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ...” NCT02389036 ↗ “OBJECTIVE: To evaluate the efficacy and safety of topical ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution relative to ciprofloxacin, 0.3%, otic solution...” PMID 28006041 ↗ Apr 2017 “The purpose of this study is to compare the relative bioavailability of ciprofloxacin 1000 mg ER tablets of Dr.Reddy's with that of CIPRO® XR 1000 mg of Bayer Pharmaceuticals...” NCT01372358 ↗ “This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv)...” NCT02168816 ↗ “In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral...” NCT01111253 ↗ “Once the child starts tolerating oral intake and becomes clinically improved, the treatment will be changed to oral ciprofloxacin (20 mg/kg/day) divided into 2 divided doses)...” NCT04030741 ↗ “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ “Ciprofloxacin, 0.3%, plus fluocinolone acetonide, 0.025%, otic solution seems to be efficacious and safe in treating acute otitis externa (AOE) compared with ciprofloxacin,...” PMID 35834251 ↗ Jul 2022 “The purpose of this study is to assess the efficacy of 3 days of azithromycin (AZI) compared to 3 days of ciprofloxacin (CIP) (standard-of-care) for the treatment of children...” NCT03854929 ↗ “Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and...” NCT00713999 ↗ “Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in...” NCT05581706 ↗ “PrimeC is a fixed-dose oral combination of celecoxib and ciprofloxacin designed to target ALS-related mechanisms, including neuroinflammation, iron homeostasis, and...” PMID 41837970 ↗ May 2026 “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗ “* Ciprofloxacin : IV : 400mg/8h if Pseud spp ; 400mg/12h for others Gram-negative bacilli strains; PO : 1gr/12h if Pseud spp ; 750mg/12h for others Gram-negative bacilli strains” NCT05074147 ↗ “500 mg Metronidazole tablet+ 500 mg Ciprofloxacin tablet crushed into powder and mixed together with salline to form a creamy mix to be placed inside the root canal for 1 week.” NCT04593238 ↗ “It was prepared by removing the coating and crushing of antibiotic ciprofloxacin500mg,metronidazole 400mg,, and clindamycin tablets separately using a mortar and pestle.” NCT06174909 ↗ “The TAP was freshly prepared and proportioned in equal parts by volume (metronidazole, minocycline, and ciprofloxacin=1:1:1) before the scheduled treatment appointment.” NCT04547764 ↗ “A modified triple antibiotic paste consisting of ciprofloxacin, metronidazole, and clindamycin (1:1:1 by weight) will be placed in the canal using a Lentulo spiral.” NCT07123792 ↗ “mix metronidazole, ciprofloxacin and minocycline in ratio 1:1:1 with normal saline and placed as intra canal medicament during first visit of root canal treatment.” NCT06821763 ↗ “The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.).” NCT01761214 ↗ “During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin” NCT02682485 ↗ “Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.” NCT03159754 ↗ “Hoshino et al. recommended a ratio of 1:1:1 of metronidazole (500 mg), minocycline (100 mg) and ciprofloxacin (200 mg) for the 3Mix formulation” NCT03763110 ↗ “ciprofloxacin, metronidazole \& minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.” NCT00881907 ↗ “2 tablets of PrimeC administered twice daily (4 tablets a day), total daily dose of 1360 mg ciprofloxacin and 136 mg celecoxib orally.” NCT06185543 ↗ “a single-dose intratympanic, intraoperative, thermosensitive, otic suspension of ciprofloxacin (OTO-201) in children requiring TTP.” PMID 26985629 ↗ May 2016 “The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole” NCT03303677 ↗ “Intracanal medicament paste composed of Ciprofloxacin, Metronidazole, and Minocycline. Placed in the root canal for several weeks.” NCT07239739 ↗ “The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid.” NCT04238091 ↗ “pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin” NCT06478940 ↗ “Penicillin allergy: Ciprofloxacin 500 mg, one tablet every 12 hours + Metronidazole 500 mg, two tablets every 8 hours.” NCT06517264 ↗ “For children younger than 7 years: PO Ciprofloxacin 10mg per Kg twice a day (up to 250mg twice a day) for 3 weeks” NCT02033408 ↗ “The material is a combination of 3Mix (cefixime, metronidazole, and ciprofloxacin) and a statin (Simvastatin).” NCT06925490 ↗ “ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.” NCT00881491 ↗ “Includes antibiotics such as amoxicillin, cephalexin, ciprofloxacin, and trimethoprim-sulfamethoxazole.” NCT06080698 ↗ “The triple antibiotic paste will be prepared using metronidazole , ciprofloxacin and doxycycline .” NCT05445362 ↗ “Group 1 (Control): LSTR using Triple Antibiotic Paste (Ciprofloxacin + Metronidazole + Cefixime).” NCT07264842 ↗ “oral quinolone (ciprofloxacin or levofloxacin) or oral macrolide (azithromycin or clarithromycin)” NCT03220074 ↗ “A total of 10 intrauterine infusions of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml” NCT05205993 ↗ “ciprofloxacin metronidazole minocycline paste will be :placed in the canal and kept for 4 weeks.” NCT04319575 ↗ “then Ciprofloxacin was used instead and started within 120 minutes of the procedure at 400mg IV” NCT02579161 ↗ “Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin” NCT05724628 ↗ “and ciprofloxacin 750 mg to keep at home for initial use if symptoms of infection develop” NCT07202052 ↗ “The fluoroquinolone antibiotics included ciprofloxacin, levofloxacin, and moxifloxacin.” NCT04879030 ↗ “intrauterine infusion of 3ml of ciprofloxacin at a concentration of 200 mg/100 ml” NCT04447625 ↗ “* Active substance: Ciprofloxacin 0.3% * Pharmaceutical form: Ophthalmic solution” NCT03519516 ↗ “DAP is a combination of two antibiotics which are ciprofloxacin and metronidazole” NCT05600023 ↗ “PRP (nafcillin or flucloxacillin) or vancomycin, plus aztreonam or ciprofloxacin” NCT00303589 ↗ “broad spectrum antibiotics (vancomycin, ciprofloxacin, metronidazole) for 7 days” NCT03051698 ↗ “Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.” NCT06443502 ↗ “3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin” NCT03084601 ↗ “Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)” NCT01731236 ↗ “fosfomycin 3g once oral, ciprofloxacin 250 mg oral twice a day for 5 days” NCT07686055 ↗ “Ciprodex (0.3% Ciprofloxacin and Dexamethasone 0.1% Otic Suspension)” NCT01359098 ↗ “Ciprofloxacin, 500 mg 2/day \& Metronidazole (Flagyl), 500 mg 3/day.” NCT05024188 ↗ “Oral antibiotics: 1) ciprofloxacin, 2) trimethoprim-sulfamethoxazole” NCT07236944 ↗ “1:1 metronidazole and ciprofloxacin are mixed with propylene glycol” NCT05079802 ↗ “Ciprofloxacin and Metronidazol will be used as oral antibiotics” NCT01572558 ↗ “tienam,meropenem,levofloxacin,ciprofloxacin,amikacin,gentamicin” NCT03622450 ↗ “Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9” NCT01329588 ↗ “Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited” NCT01372345 ↗ “Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt)” NCT03533231 ↗ “ciprofloxacin (Cipro, 750 mg tablets, Biofarma, Turkiye)” NCT06818578 ↗ “an oral fluoroquinolone (ciprofloxacin 750mg tw/d)” NCT06368804 ↗ “ciprofloxacin 250 mg oral twice a day for 5 days” NCT05726318 ↗ “Arm 1: ciprofloxacin 500 mg once pre-procedure” NCT05719285 ↗ “clindamycin, ciprofloxacin and metronidazole” NCT06006663 ↗ “1 g ciprofloxacin (500 mg morning and night)” NCT06055257 ↗ “Ciprofloxacin, Metronidazole, & Minocycline” NCT01976065 ↗ “20 mg/kg of the antibiotic, ciprofloxacin.” NCT06149676 ↗ “* Ciprofloxacin IV and PO 750to 1000mg/12h” NCT02123628 ↗ “Ciprofloxacin or Rifaximin for 10 days.” NCT04003181 ↗ “Ciprofloxacin 500 mg, twice daily;” NCT04150250 ↗ “500 mg Ciprofloxacin twice daily” NCT05384197 ↗ “Ciprofloxacin 400 mg IV/12h” NCT02795949 ↗ “500 mg Ciprofloxacin tab” NCT05677945 ↗ “Ciprofloxacin*” NCT02099240 ↗ “ciprofloxacin” NCT06149676 ↗ “Ciprofloxacin” NCT05846399 ↗ “ciprofloxacin” NCT05750966 ↗ |
| Known as | Amox-clav | “Amox-clav given to eligible women as per existing protocol, which is 625mg three times a day, for a week” NCT03459599 ↗ |
| Known as | Amoxycillin + Clavulanic acid | “None of the authors have received any form of honoraria, funding, grant, employment or have financial interest in the manufacturer of Co-Amoxiclav™ (Amoxycillin + Clavulanic...” PMID 31296180 ↗ Jul 20191“Three hospitals where the current protocol was to administer prophylactic amoxycillin-clavulanic acid served as the sites of recruitment.” PMID 31296180 ↗ Jul 2019 |
| Known as | ARD-3150 | “In the recent phase-3 ORBIT trials, 48 weeks' treatment with ARD-3150 (inhaled liposomal ciprofloxacin) did not significantly improve symptoms” PMID 32554534 ↗ Oct 2020 |
| Known as | BAYO9867 | “Ciprofloxacin (BAYO9867)” NCT00668044 ↗ |
| Known as | BAYQ3939 | “Ciprofloxacin (BAYQ3939) dry powder for inhalation” NCT02106832 ↗13“Ciprofloxacin (Cipro InhaIe, BAYQ3939)” NCT01072942 ↗ “Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT00645788 ↗ “Cipro Inhale (Ciprofloxacin, BAYQ3939)” NCT01168895 ↗ “Ciprofloxacin (Cipro inhale, BAYQ3939)” NCT01052298 ↗ “Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT01538667 ↗ “Ciprofloxacin (PulmoSphere, BAYQ3939)” NCT00961038 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00668122 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00481689 ↗ “Drug: Ciprofloxacin DPI (BAYQ3939)” NCT01764841 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00676533 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT00930982 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT01561794 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT00910351 ↗ |
| Known as | Ciloxan | “Groups 1, 2 and 3 received topical ofloxacin 0.3% (Ocuflox), ciprofloxacin 0.3% (Ciloxan) and levofloxacin (Quixin) respectively;” PMID 18211932 ↗ Jan 2008 |
| Known as | CIP | “The purpose of this study is to assess the efficacy of 3 days of azithromycin (AZI) compared to 3 days of ciprofloxacin (CIP) (standard-of-care) for the treatment of children...” NCT03854929 ↗1“Ciprofloxacin hydrochloride (CIP) in chitosan coated PLGA nanoparticles (CIP-CS-PLGA-NPs) and free CIP were embedded in Pluronic® 407/188 to form thermosensitive gels(F1) and...” NCT05442736 ↗ |
| Known as | Cipro | “Double antibiotic paste (DAP): metronidazole (Flagyl, Sanofi-Aventis, Turkey) and ciprofloxacin (Cipro, Biofarma, Turkey) powdered antibiotics were stored and sealed in...” NCT05581706 ↗8“Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic” NCT02189668 ↗ “Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)” NCT01731236 ↗ “All subjects will be treated with Cipro, an antibiotic, for 5 days.” NCT00654108 ↗ “ciprofloxacin (Cipro, 750 mg tablets, Biofarma, Turkiye)” NCT06818578 ↗ “Group 1: Topical 0.3% Ciprofloxacin [Cipro]” NCT04204954 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT00930982 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT01561794 ↗ “Ciprofloxacin (Cipro, BAYQ3939)” NCT00910351 ↗ |
| Known as | Cipro InhaIe | “Ciprofloxacin (Cipro InhaIe, BAYQ3939)” NCT01072942 ↗ |
| Known as | Cipro inhale | “Ciprofloxacin (Cipro inhale, BAYQ3939)” NCT01052298 ↗3“Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT01538667 ↗ “Cipro Inhale (Ciprofloxacin, BAYQ3939)” NCT01168895 ↗ “Ciprofloxacin (Cipro Inhale, BAYQ3939)” NCT00645788 ↗ |
| Known as | Cipro IR | “Cipro IR (Ciprofloxacin, BAYQ3939)” NCT00668122 ↗ |
| Known as | CIPRO IV | “Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]” NCT05162625 ↗ |
| Known as | Cipro XR | “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00668122 ↗4“Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00481689 ↗ “Cipro XR (Ciprofloxacin, BAYQ3939)” NCT00676533 ↗ “Cipro® XR Tablets 1000 mg” NCT00649662 ↗ “Cipro® XR Tablets (500 mg” NCT00649155 ↗ |
| Known as | Ciprocin | “Ciprofloxacin (Ciprocin 250 mg tablets; EPICO, Cairo, Egypt)” NCT03533231 ↗ |
| Known as | Ciprofloxacin (Cetraxal) | “Ciprofloxacin (Cetraxal)” NCT02168816 ↗ |
| Known as | ciprofloxacin (Cifran) | “ciprofloxacin (Cifran)” NCT01761214 ↗ |
| Known as | Ciprofloxacin hydrochloride | “Ciprofloxacin hydrochloride (CIP) in chitosan coated PLGA nanoparticles (CIP-CS-PLGA-NPs) and free CIP were embedded in Pluronic® 407/188 to form thermosensitive gels(F1) and...” NCT05442736 ↗ |
| Known as | Ciprofloxacin Inhale | “Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days” NCT01072942 ↗ |
| Known as | Ciprofloxacin Ophthalmic solution | “Ciprofloxacin Ophthalmic solution” NCT03519516 ↗ |
| Known as | Ciprofloxacin tablets USP 39 | “Chemotherapeutic agents used are metronidazole tablets 500 mg (Flagyl®, Sanofi, Egypt), ciprofloxacin tablets 500 mg (Ciprofloxacin tablets USP 39®, European pharmaceuticals,...” NCT06158451 ↗ |
| Known as | Ciproxin | “Intralesional ciprofloxacin (2 mg/ml, 100 ml, Ciproxin®, Bayer Schering pharma AG, Germany), each lesion was injected based on lesion size (2 mg/cm2).” NCT06798402 ↗ |
| Known as | Ciproxin - ciprofloxacin | “Ciproxin ® - ciprofloxacin” NCT01400750 ↗ |
| Known as | Co-Amoxiclav | “None of the authors have received any form of honoraria, funding, grant, employment or have financial interest in the manufacturer of Co-Amoxiclav™ (Amoxycillin + Clavulanic...” PMID 31296180 ↗ Jul 2019 |
| Known as | CPFX | “Ciprofloxacin (CPFX) is a potential alternative in patients with febrile neutropenia (FN) because of its activity against Gram-negative organisms.” PMID 23317527 ↗ Jan 2013 |
| Known as | FoamOtic Cipro | “Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro (0.3% Ciprofloxacin Otic Foam) Compared to Twice-Daily Dosing of Ciloxan” NCT01157819 ↗ |
| Known as | Otiprio | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03347461 ↗ |
| Known as | OTO-201 | “a single-dose intratympanic, intraoperative, thermosensitive, otic suspension of ciprofloxacin (OTO-201) in children requiring TTP.” PMID 26985629 ↗ May 20162“6 mg OTO-201 (sustained-release suspension of ciprofloxacin)” NCT02719158 ↗ “OTO-201 (ciprofloxacin)” NCT02600559 ↗ |
| Known as | Pulmaquin | “inhaled Pulmaquin (ciprofloxacin dispersion for inhalation)” NCT01515007 ↗ |
| Known as | PulmoSphere | “Ciprofloxacin (PulmoSphere, BAYQ3939)” NCT00961038 ↗ |
| Action | Inhibit | “Ciprofloxacin suppresses the gram negative aerobic bacterial flora including E.coli strains” NCT00609973 ↗ |
| Modality | Small molecule | “Although optimization of the fluoroquinolone dosage increases the efficacy of this class of drugs against bacterial infections” PMID 19563257 ↗ Aug 2009 |
| Route | Oral | “ciprofloxacin, clofazimine, ethambutol, and rifampin (all taken orally)” NCT00000641 ↗ |
| Target | CYP1A2 | “Ciprofloxacin is moderate inhibitor of cytochrome P450 1A2 (CYP1A2)” NCT00785980 ↗ |